Phylogenetic analysis of HIV transmission among different ethnic MSM groups in the UK. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012.. 2012.
Population based study indicates viral genetic effect on HIV virulence is small but significant. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012.. 2012.
The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK. Antivir Ther. 17:599-603.. 2012.
Significant HIV-1 subtype differences observed in the development of accessory mutations associated with high-level resistance to reverse transcriptase inhibitors. International Workshop on HIV & Hepatitis Virus Resistance and Curative Strategies, 5-9 June 2012. Antiviral Therapy 17 Suppl 1:A84.. 2012.
Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ. 345:e5253.. 2012.
Transmission dynamics of CRF50_A1D across most at risk communities in the UK. 19th International HIV Dynamics & Evolution Conference, 25-28 April 2012.. 2012.
Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score PLoS One. 6:e25665.. 2011.
The contribution of recent infections to HIV-1 transmission clusters in the UK. 18th International HIV Dynamics and Evolution Conference, 1-4 May 2011.. 2011.
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother. 66:1886-96.. 2011.
Different drug-resistance development in HIV-1 infected patients failing a first-line antiretroviral therapy containing NNRTIs. IAS, 17-20 July 2011.. 2011.
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 11:363-71.. 2011.
Genotypic resistance testing in routine clinical care. Curr Opin HIV AIDS. 6:251-7.. 2011.
HIV transmission dynamics. Keystone Conference on HIV Evolution, Genomics and Pathogenesis, 26-31March 2011.. 2011.
The impact of HIV drug resistance testing on changes to treatment. AIDS. 25:603-10.. 2011.
Impact of Viral Subtype on Immunologic and Clinical Disease Progression in Antiretroviral-naïve HIV-infected Adults. 18th Conference on Retroviruses and Opportunistic Infections, 27 Feb - 2 Mar 2011.. 2011.
Mapping the circulation of HIV-1 recombinants among MSM. 18th Conference on Retroviruses and Opportunistic Infections, 27 Feb - 2 Mar 2011.. 2011.
Phylogeographic and Risk Group Characteristics of HIV Subtype A Transmission in the UK. 18th Conference on Retroviruses and Opportunistic Infections, 27 Feb - 2 Mar 2011.. 2011.
Phylogeographic and risk group characteristics of HIV-1 Subtype A transmission in the UK. 18th International HIV Dynamics and Evolution Conference, 1-4 May 2011.. 2011.
Predicting NNRTI resistance - do polymorphisms matter? 18th Conference on Retroviruses and Opportunistic Infections, 27 Feb - 2 Mar 2011.. 2011.
Prevalence and predictors of protease inhibitor (PI) mutations in HIV-infected UK adults treated with ritonavir-boosted lopinavir as their first PI. 17th Annual Conference of the British HIV Association, 6-8 April 2011.. 2011.